ReviewDiagnostics (Basel, Switzerland)2026
IQGAP Family Proteins in Colorectal Cancer: Molecular Mechanisms and Prognostic Implications.
Review in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, and the molecular mechanisms driving its progression and metastasis remain incompletely understood. Increasing evidence highlights the role of IQ motif-containing GTPase-activating proteins (IQGAPs)-a family of scaffold proteins consisting of IQGAP1, IQGAP2, and IQGAP3-in regulating multiple signaling pathways involved in tumor development. This narrative review provides an overview of the molecular roles of IQGAP family proteins in CRC, focusing on their involvement in oncogenic signaling and their potential prognostic significance. Current evidence suggests that IQGAP family members play distinct and sometimes opposing roles in CRC biology. IQGAP1 is frequently overexpressed and acts as a scaffold that activates ERK/MAPK and β-catenin signaling, promoting proliferation, invasion, and metastasis. In contrast, IQGAP2 exhibits tumor-suppressive properties, with reduced expression associated with more aggressive disease and unfavorable outcomes. Meanwhile, IQGAP3 has emerged as a potential oncogenic driver, where its upregulation correlates with enhanced tumor growth, metastatic potential, and poorer survival, possibly through PI3K-related signaling. Together, these findings highlight the context-dependent roles of IQGAP proteins in CRC and suggest their potential as novel biomarkers and therapeutic targets. Further validations are needed to explore the clinical utility of IQGAP proteins in CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.